In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.Subject terms
Nat Rev Clin Oncol. 2021; 18(3): 170–186.Published online 2020 Dec 8. doi: 10.1038/s41571-020-00447-zPMCID: PMC7904519PMID: 33293629
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller,1Martin van den Bent,2Matthias Preusser,3Emilie Le Rhun,4,5,6,7Jörg C. Tonn,8Giuseppe Minniti,9Martin Bendszus,10Carmen Balana,11Olivier Chinot,12Linda Dirven,13,14Pim French,15Monika E. Hegi,16Asgeir S. Jakola,17,18Michael Platten,19,20Patrick Roth,1Roberta Rudà,21Susan Short,22Marion Smits,23Martin J. B. Taphoorn,13,14Andreas von Deimling,24,25Manfred Westphal,26Riccardo Soffietti,21Guido Reifenberger,27,28 and Wolfgang Wick29,30Author informationArticle notesCopyright and License informationDisclaimerThis article has been cited by other articles in PMC.Go to:
Abstract
In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy — Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.Subject terms: CNS cancer, CNS cancer
Go to: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904519/
